Immunotherapy in stage IV
What will happen?
•
A role in 1
st
line treatment
As monotherapy for selected populations (strong PDL1+);
low percentage of patients
Combination of anti-CTLA4 + anti-PD1/anti-PDL1 for selected patients (PDL1-?);
less
relevance of predictive markers
Combination of CT + anti-PD1/anti-PDL1;
less relevance of predictive markers
•
More predictive markers beyond PDL1 expected
•
Combination immunotherapy after immunotherapy PD??
